Lucid Diagnostics Inc.

NASDAQ:LUCD

Medical - Devices

Healthcare
$0.41 +3.80%

+$0.04 today

Market cap
$79.38M
Beta
1.08
P/E (TTM)
-2.3
EPS (TTM)
-$0.44
52W Low $0.90High $1.63

Volume 2.70M

Average 0.84M

LUCD Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Lucid Diagnostics Inc.NASDAQ: LUCD

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $1.85M rose 19.1% year over year, ahead of the +2.8% change in trailing-twelve-month cost of revenue. Sequentially, it fell 0.7% from the prior quarter. Over 3 fiscal years it compounded at +27.8% a year.

Context

  • Cost of revenue amounted to 160.3% of revenue in FY2025, down 29.9 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +19.1% holds above the trailing-twelve-month pace of +2.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.85M-0.7% QoQ
Last fiscal yearDec 2025
$7.54M-8.8% YoY
LTMMar 2026
$7.19M+2.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.1%——
1 year-8.8%——
3-year CAGR+27.8%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
7.54M USD
Year-over-year change
-8.8%
4-year CAGR
+89.5%

Cost of Revenue vs competitors

How LUCD compares with its peers on the latest reported figures

  • LUCD's LTM Mar 2026 cost of revenue of $7.19M is the 7th highest of the 10 companies compared; the peer median is $13.48M.
  • Its year-over-year change of +2.8% is the 8th highest of 10, against a peer median of +13.5%.
  • Cost of revenue amounts to 140.0% of revenue for LUCD, versus a peer median of 51.7%.
LUCD Competitors Peer median
Cost of Revenue for LUCD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OWLTOwlet, Inc.LTM Mar 2026$52.61M +30.6%+4.4%49.1%
APYXApyx Medical CorporationLTM Mar 2026$37.86M +65.4%+30.0%67.7%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$30.12M +8.2%+0.4%87.6%
SCLXScilex Holding CompanyLTM Mar 2026$15.25M +7.1%+12.1%45.0%
RCELAVITA Medical, Inc.LTM Mar 2026$13.48M +29.5%+28.4%18.6%
SEERSeer, Inc.LTM Mar 2026$7.78M -27.0%-0.2%51.7%
LUCDLucid Diagnostics Inc.LTM Mar 2026$7.19M +2.8%+27.8%140.0%
IRDOpus Genetics, Inc.LTM Mar 2026$6.04M -22.4%—50.4%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.33M +13.5%-8.4%71.7%
STSSSkyAI, Inc.LTM Mar 2026$820.02K +29.4%-1.9%206.6%
Peer median (excluding LUCD) $13.48M+13.5%+2.4%51.7%

Competitors are the stored peer set for LUCD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue500K377K2.43M4.35M4.71M
Cost of Revenue585K3.61M8.48M8.27M7.54M
Gross Profit(85K)(3.24M)(6.05M)(3.92M)(2.84M)
Gross Margin-17.0%-858.6%-249.2%-90.2%-60.3%
Research & Development9.3M11.47M7.25M5.99M5.68B
Selling, General & Admin18.04M39.82M35.66M36.62B41.58B
Operating Expenses27.33M52.93M42.43M42.13M46.8M
Depreciation & Amortization4K1.94M2.5M1.17M872K
EBITDA(27.42M)(54.23M)(49.75M)(44.34M)(57.12M)
EBITDA Margin-5483.0%-14383.8%-2049.1%-1020.2%-1213.7%
Operating Income(27.42M)(56.17M)(48.48M)(46.05M)(49.64M)
Operating Margin-5483.8%-14899.5%-1996.8%-1059.6%-1054.8%
Interest Income088K424K322K386K
Interest Expense659K8K416K26K22K
Other Income / Expenses(659K)0(4.18M)523K(8.37M)
Income Before Tax(28.08M)(56.17M)(52.67M)(45.53M)(58.01M)
Pre-Tax Margin-5615.6%-14899.5%-2169.1%-1047.6%-1232.7%
Income Tax Expense00000
Net Income(28.08M)(56.17M)(52.67M)(45.53M)(58.01M)
Net Margin-5615.6%-14899.5%-2169.1%-1047.6%-1232.7%
EPS (Basic)(0.78)(1.55)(1.26)(1.05)(0.69)
EPS (Diluted)(0.78)(1.55)(1.26)(1.05)(0.69)
Weighted Avg Shares36.06M36.17M41.76M50.52M101.95M
Weighted Avg Shares (Diluted)36.06M36.17M41.76M50.52M101.95M

Lucid Diagnostics Inc.

NASDAQ:LUCD

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.